Entacapone Disease Interactions
There are 3 disease interactions with entacapone.
Dopamine agonists (applies to entacapone) hypotension
Major Potential Hazard, Moderate plausibility.
Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation. Therapy with dopamine agonists should be monitored carefully in patients with Parkinson's disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.
References
- Hoehn MM "Levodopa-induced postural hypotension. Treatment with fludrocortisone." Arch Neurol 32 (1975): 50-1
- Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson's disease." Eur Neurol 30 (1990): 194-9
- "Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn (2001):
- "Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals (2001):
- "Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals (2001):
- "Product Information. Mirapex (pramipexole)." Boehringer Ingelheim (2001):
- "Product Information. Requip (ropinirole)." SmithKline Beecham (2001):
- "Product Information. Comtan (entacapone)." Novartis Pharmaceuticals (2001):
- "Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA (2006):
- "Product Information. Neupro (rotigotine)." Schwarz Pharma (2007):
- "Product Information. Xadago (safinamide)." US WorldMeds LLC (2017):
Dopaminergic antiparkinson agents (applies to entacapone) psychosis
Major Potential Hazard, Moderate plausibility.
Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis. Hallucinations and psychotic-like behavior have been reported with dopaminergic medications. In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson's disease and may decrease the effectiveness of these drugs.
References
- "Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn (2001):
- "Product Information. Mirapex (pramipexole)." Boehringer Ingelheim (2001):
- "Product Information. Requip (ropinirole)." SmithKline Beecham (2001):
- "Product Information. Comtan (entacapone)." Novartis Pharmaceuticals (2001):
- "Product Information. Lodosyn (carbidopa)." DuPont Pharma (2001):
- "Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA (2006):
- "Product Information. Neupro (rotigotine)." Schwarz Pharma (2007):
- "Product Information. Xadago (safinamide)." US WorldMeds LLC (2017):
Entacapone (applies to entacapone) hepatic impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Entacapone should be used with caution in patients with hepatic impairment, as the AUC and Cmax of the drug approximately doubled in patients with documented liver disease compared to patients with normal liver function.
References
- "Product Information. Comtan (entacapone)." Novartis Pharmaceuticals (2001):
Entacapone drug interactions
There are 273 drug interactions with entacapone.
Entacapone alcohol/food interactions
There is 1 alcohol/food interaction with entacapone.
More about entacapone
- entacapone consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (15)
- Drug images
- Latest FDA alerts (2)
- Side effects
- Dosage information
- During pregnancy
- Drug class: dopaminergic antiparkinsonism agents
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.